What is Chardan Capital’s Forecast for TNYA FY2025 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($0.71) for the year, up from their previous forecast of ($1.10). Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Several other research analysts have also issued reports on TNYA. Morgan Stanley dropped their target price on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, March 12th. HC Wainwright lowered their target price on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, Canaccord Genuity Group reduced their price target on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Trading Down 1.9 %

Tenaya Therapeutics stock opened at $0.64 on Thursday. Tenaya Therapeutics has a 12-month low of $0.39 and a 12-month high of $5.32. The firm has a 50-day moving average price of $0.93 and a 200-day moving average price of $1.71. The firm has a market capitalization of $56.18 million, a PE ratio of -0.45 and a beta of 2.83.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04.

Insiders Place Their Bets

In related news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the transaction, the insider now owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. The trade was a 262.62 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 19,621 shares of company stock worth $10,595 in the last three months. Corporate insiders own 32.76% of the company’s stock.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Synovus Financial Corp bought a new stake in shares of Tenaya Therapeutics in the 3rd quarter valued at about $28,000. Woodline Partners LP purchased a new position in Tenaya Therapeutics during the 4th quarter worth $28,000. Commerce Bank purchased a new stake in Tenaya Therapeutics in the fourth quarter valued at about $29,000. Mariner LLC purchased a new stake in shares of Tenaya Therapeutics during the fourth quarter worth about $30,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Tenaya Therapeutics during the fourth quarter valued at about $32,000. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.